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ABSTRACT
Acute leukemia is a constellation of rapidly progressing
diseases that affect a wide range of patients regardless
of age or gender. Traditional treatment options for
patients with acute leukemia include chemotherapy
and hematopoietic cell transplantation. The advent of
cancer immunotherapy has had a significant impact on
acute leukemia treatment. Novel immunotherapeutic
agents including antibody-drug conjugates, bispecific
T cell engagers, and chimeric antigen receptor T cell
therapies have efficacy and have recently been approved
by the US Food and Drug Administration (FDA) for the
treatment of patients with acute leukemia. The Society
for Immunotherapy of Cancer (SITC) convened a panel of
experts to develop a clinical practice guideline composed
of consensus recommendations on immunotherapy for
the treatment of acute lymphoblastic leukemia and acute
myeloid leukemia.

INTRODUCTION
The acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid
leukemia (AML), are rapidly progressing
forms of leukemias defined by high percentages of blasts in the blood and bone marrow
and by the predominant lineages of malignant cells.1 In 2020, an estimated 26,090
cases of acute leukemias will be diagnosed in
the US and 12,700 deaths are anticipated.2
In children, leukemia is the most common
hematologic malignancy, and the incidence
of childhood leukemia has steadily increased
every year.3 Advances in molecular diagnostics over the past several decades have
further defined multiple disease subtypes,
differentiated by the presence of specific
genetic markers, which have informed risk-
based treatment paradigms to reduce toxicity
in low-
risk patients while pursuing more

aggressive therapies for those with a high risk
of relapse.4–7
Standard treatment paradigms for acute
leukemia have centered on high-
intensity
induction chemotherapy to achieve complete
remission (CR) followed by allogeneic hematopoietic cell transplant (allo-HCT) in certain
patients8–10 to eradicate residual disease
through the “graft versus leukemia” effect
mediated by the donor’s immune cells.11–13
However, allo-
HCT is not indicated for all
patients and a major ongoing challenge in the
field is that few chemotherapy-based options
are effective following relapse after allo-HCT
or for patients who develop chemotherapy-
refractory disease.13 14
Immunotherapeutic approaches have
dramatically altered the treatment landscape across a variety of disease settings,
including hematological cancers. In recent
years, novel agents including monoclonal
antibodies, bispecific antibodies, antibody-
drug conjugates (ADCs), and engineered
chimeric antigen receptor (CAR) T cells have
been approved by the US Food and Drug
Administration (FDA), offering additional
options beyond standard regimens and deep
and durable responses in some patients.15–18
Although ADCs may not be classified as a
traditional form of immunotherapy, there is
evidence of immunomodulatory activity by
these agents.19
While immunotherapies for acute leukemia
have demonstrated efficacy in a number of
large-scale, randomized trials,15 20 21 clinical
experience with some of these novel agents
is still somewhat limited. To support the
oncology community and provide expert,
evidence-
based
recommendations,
the
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Society for Immunotherapy of Cancer (SITC) published
consensus recommendations in December 2016 on
the role of immunotherapy in the treatment of hematological malignancies.22 Since 2016, however, rapid
advances in the field have brought about a wider array of
immunotherapy-based treatment options for each of the
individual disease states discussed in the original guidelines: acute leukemia, lymphoma, and multiple myeloma.
Thus, the SITC Cancer Immunotherapy Guidelines—
Hematologic Malignancies Subcommittee determined
that stand-alone guidelines are needed. To form up-to-
date recommendations on the use of immunotherapy
for the treatment of patients with acute leukemia, SITC
convened a panel of experts to develop a new clinical
practice guideline. This publication represents an update
to the previously published consensus statement based on
a more recent assessment of the peer-reviewed literature
and the clinical experience of expert panel participants.
These recommendations are not intended to supplant
sound clinical judgment but rather to provide clinicians
with the most current thinking on how experts integrate
immunotherapy into the treatment of patients with acute
leukemia.

METHODS
SITC Acute Leukemia Immunotherapy Guideline Expert Panel
The SITC Acute Leukemia Guideline Expert Panel
consisted of 17 participants, including medical oncologists, hematologists, a hematopathologist, a leukemia
research nurse, and a patient advocate. Every clinical
Expert Panel member reported previous experience/
knowledge regarding the use of immunotherapy for the
treatment of patients with leukemia. The panel members
met in person and communicated regularly via email and
teleconference. In addition, they completed a survey (see
online supplementary file 1) addressing clinical topics
concerning the use of cancer immunotherapy for the
treatment of patients with acute leukemia, which helped
form the basis for these recommendations.
Consensus statement policy
The Institute of Medicine’s (IOM) Standards for Developing Trustworthy Clinical Practice Guidelines were used
as a model to develop the consensus recommendations
in this manuscript. IOM standards dictate that guideline
development be led by a multidisciplinary team using
a transparent process where both funding sources and
conflicts of interest are readily reported. Recommendations are based on literature evidence, where possible,
and clinical experience, where appropriate.23 For transparency, a draft of this consensus statement was made
publicly available for comment after journal submission.
All comments were considered for inclusion into the
final manuscript. This consensus statement is intended to
provide guidance and is not a substitute for the professional judgment of individual treating physicians.
2

Evidence and consensus ratings
Recommendations were derived from evidence within
the published literature along with responses to a clinical
questionnaire that addressed current practices in the use
or recommendation for use of immunotherapy agents
(online supplementary file 1). SITC Cancer Immunotherapy Guidelines provide recommendations based on
peer-reviewed literature and consensus within the expert
panel. Consensus was defined as ≥75% agreement among
expert panel members.
Conflicts of interest policy
As per SITC policy, expert panel members managed
potential competing interests through disclosure of all
financial relationships that might result in actual, potential, or perceived conflicts of interest. No commercial
funding was provided to support the expert panel, literature review, or the preparation of this manuscript.
Literature review process
The MEDLINE database was used to search the scientific
literature for current therapies related to acute leukemia
and immunotherapy, including clinical trials, meta-
analyses, practice guidelines, and research in humans.
The search terms included among others “acute
lymphoblastic leukemia,” “acute myeloid leukemia,”
“blinatumomab,” “inotuzumab ozogamicin,” “tisagenlecleucel,” “CAR T AND leukemia,” “gemtuzumab
ozogamicin,” “immunotherapy AND leukemia,” and
“immunotherapy toxicity.” Manuscripts retrieved by the
search were screened to include only papers with clinically accurate and relevant information and to remove
duplicate articles from independent searches. The reference library was supplemented with additional articles
identified by the panel as appropriate and necessary for a
comprehensive literature review, resulting in a final bibliography of 141 manuscripts.

DIAGNOSTICS PRIOR TO IMMUNOTHERAPY FOR NEWLY
DIAGNOSED PATIENTS WITH ACUTE LEUKEMIA
A number of clinical guidelines have been developed
for the workup and diagnosis of acute leukemia. Initial
workup provides disease classification, risk stratification,
and a better understanding of both disease biology and
potential treatment options.1 5 6 24–26 Selection of appropriate diagnostics to initiate immunotherapies is under
investigation. Only in a select few situations has consensus
been achieved on how to determine whether a patient
is a strong candidate for immunotherapy. Further, if a
patient is eligible for two different immunotherapies, it
is challenging to identify the treatment option that will
provide maximal benefit. Potential diagnostic evaluations
for patients with acute leukemia being considered for
immunotherapy are discussed below.
A number of diagnostics are available for the initial
workup of a patient suspected to have acute leukemia.
Workup typically includes history and physical
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examination, complete blood counts (CBC) and leucocyte differential counts, platelets, electrolytes, liver function tests, prothrombin time (PT), partial thromboplastin
time (PTT), international normalized ratio (INR), fibrinogen, lactate dehydrogenase (LDH), uric acid, human
leucocyte antigen (HLA) typing for patients who are
candidates for allo-HCT, chest X-ray and CT/MRI scans if
clinically indicated, echocardiogram, and a lumbar puncture if neurological symptoms are present.5 6 24 27 Bone
marrow biopsy/aspirate with cytogenetics (karyotype and
fluorescence in situ hybridization (FISH)), immunophenotyping, and molecular studies including next generation sequencing, are performed to diagnose and classify
disease characteristics. Cytochemical studies can also
help to differentiate between ALL and AML, but do not
traditionally replace immunophenotyping. Appropriate
sensitivity of all assessment techniques must be verified
to ensure that measurable/minimal residual disease
(MRD) status can also be assessed in future management
stages.24–26
Acute leukemia can be associated with a variety of
genetic mutations that may serve as markers for MRD
or be targetable with drugs. ALL can be associated with
a variety of genetic mutations. The American Society of
Clinical Oncology/College of American Pathologists/
American Society of Hematology (ASCO/CAP/ASH)
guidelines for the workup of acute leukemia recommend
a number of genetic tests to identify different mutations.
A summary of the recommended molecular tests for ALL
and AML is provided in table 1.
While molecular characterization may identify actionable mutations for targeted therapies such as tyrosine
kinase inhibitors, cell surface markers may be used to
identify potential targets for immunotherapies. The
National Comprehensive Cancer Network (NCCN) and
the European Society for Medical Oncology (ESMO)
guidelines, in addition to molecular testing, also
recommend assaying for specific cell markers, such as
CD19, CD20, and CD22 for ALL and CD33 for AML
to assess eligibility for potential antibody-
based therapies.5 26 Importantly, however, current clinical pathology
laboratories for CD19 and CD22 expression report only
the presence or percent expression, which is often not
an accurate representation of the number of molecules
or the presence of subpopulations of leukemia cells that
lack these markers.28 Subpopulations of CD19-negative
or CD22-negative or low-expression leukemia cells may
play an important role in eventual relapse. A retrospective analysis of flow cytometry archives found profound
heterogeneity in CD22 and CD19 expression across 628
B‐ALL cases. 29 Although such analyses remain strictly
for research use at this point, with the increasing use of
CD19-
specific or CD22-
specific immunotherapies, the
heterogeneity in cell surface marker expression is likely
to become an important consideration in the future.
Certain FDA-approved immunotherapies for the treatment of patients with acute leukemia require specific
disease characteristics for eligibility. For example,

Table 1 ASCO/CAP/ASH recommended genetic tests for
ALL and AML6
Disease state

Recommended tests

ALL*

t(9;22)(q34.1;q11.2); PAX5
CRLF2; JAK1
BCR-ABL1; JAK2
KMT2A (MLL); IKZF1 (for B-ALL)
CRLF2 overexpression (for B-ALL)

NOTCH1 and/or FBXW7 (for T-ALL)
AML (pediatric and FLT3-ITD; IDH1
adult)†‡
NPM1; IDH2
CEBPA; TET2
RUNX1; WT1
PML-PARA; DNMT3A
KIT (for CBF AML); TP53
RUNX1-RUNXT1/CBFB-MYH1 (for CBF
AML)
*Characterization of pediatric ALL should also include ETV6-
RUNX1, iAMP21, and trisomy 4 and 10.
†Results of RUNX1, ASXL1, and TP53 testing are recommended
by NCCN guidelines for use in risk stratification and consideration
for allo-HCT.5
‡Similar recommendations are made by the European Leukemia
Net (ELN) group for AML with additional testing for mutations in
the epigenetic regulator gene ASXL1 and FLT3-ITD allelic ratios, as
well as cell markers.4
ALL, acute lymphoblastic leukemia; allo-HCT, allogeneic
hematopoietic cell transplant ; AML, acute myeloid leukemia;
ASCO, American Society of Clinical Oncology; ASH, American
Society of Hematology; B-ALL, B-cell acute lymphoblastic
leukemia; CAP, College of American Pathologists; CBF, core-
binding factor; NCCN, National Comprehensive Cancer Network;
T-ALL, T cell acute lymphoblastic leukemia.

gemtuzumab ozogamicin (GO) for the treatment of
patients with newly diagnosed or relapsed/refractory
(RR) AML requires confirmation of CD33 positivity on
malignant cells.30 The bispecific antibody blinatumomab
that directs CD3 positive T cells to CD19-positive leukemia
cells is approved for patients with B-cell ALCL (B-ALL)
in first or second complete response (CR) with MRD
positivity after induction therapy.16 20 31–35 Therefore, it is
critical to perform phenotypic and molecular characterization of leukemic cells at diagnosis and to assist future
MRD status assessment.6 24 25 36
Several ongoing clinical trials are evaluating the safety
and efficacy of emerging immunotherapies directed
against specific cell surface markers. For example,
MGD006, a dual-
affinity T cell retargeting molecule
designed to target CD123-positive cells for recognition
and elimination by CD3-
expressing T lymphocytes, is
currently being evaluated in a phase I dose-escalation and
cohort expansion study in RR AML (NCT02152956).37
Additionally, the CD33-directed ADC IMGN779 is undergoing evaluation in a phase I trial (NCT02674763).38
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Table 2 Recommended immunotherapy-centric diagnostic
markers for acute leukemia
Disease type

Marker

Agents for
consideration

Acute lymphoblastic
leukemia

CD19

Blinatumomab

CD19

Tisagenlecleucel (patients
aged ≤25 years)

CD22

Inotuzumab ozogamicin

CD20
CD33

Rituximab
Gemtuzumab ozogamicin

Acute myeloid
leukemia

Guidelines for these and other emerging therapies will
be discussed in the emerging immunotherapies section of
this manuscript. Although many targeted therapies have
not yet been FDA approved, experimental diagnostics
may assist in referring patients to an appropriate clinical
trial. A summary of recommended immunotherapy-
centric diagnostic markers for approved therapies is in
table 2.
Panel recommendations
Cell markers at diagnosis and at the time of disease
relapse should be performed to identify potential
markers that drugs can be used for treatment.
►► Upfront diagnostics for ALL should include the cell
markers CD19, CD20, and CD22.
►► Upfront diagnostics for AML should include the cell
markers CD33 and CD123.
►► CD19+ ALL patients may be eligible for blinatumomab or tisagenlecleucel (patients aged ≤25 years).
►►

►►
►►

CD22+ ALL patients may be eligible for inotuzumab
ozogamicin.
CD33+ AML patients may be eligible for GO.

IMMUNOTHERAPY FOR THE TREATMENT OF PATIENTS WITH
ALL
Treatment of acute leukemia has rapidly evolved since
the publication of “The Society for Immunotherapy of
Cancer consensus statement on immunotherapy for the
treatment of hematologic malignancies” in 2016.22 In the
intervening years, novel immunotherapeutic approaches,
such as ADCs, dual-affinity molecules such as bispecific T
cell engagers (BiTEs), and highly successful CAR T cell
therapies, have been approved by FDA and entered the
clinic (table 3). Yet, these immunotherapies have specific
indications that must be integrated with existing treatment modalities.
Available agents and indications
The addition of immunotherapies to existing intensive
chemotherapy regimens, targeted agents, and allo-HCT
has fundamentally altered the treatment landscape for
ALL, especially in the relapsed and refractory setting.
Published guidelines from ESMO26 and NCCN39
provide recommendations for remission induction and
consolidation therapies, maintenance therapy, central
nervous system prophylaxis, and age-adopted protocols
for standard treatment regimens.
Currently, three immunotherapies are FDA approved
for the treatment of ALL: blinatumomab, inotuzumab
ozogamicin, and tisagenlecleucel. Of note, approval for
CAR T cell therapies often hinges on data from phase
II trials, as was the case for the regulatory decision
endorsing the use of tisagenlecleucel for adult patients

Table 3 FDA-approved cancer immunotherapy agents for ALL
Acute lymphoblastic leukemia (ALL)
Drug

Type

Mechanism

Approval

Blinatumomab

Bispecific T A “bispecific” antibody with
March 2018
cell engager recognition domains for CD3 and
(BiTE)
CD19 to bring T cells into proximity to
tumor cells to promote cytotoxicity

Indications

References

Adult and pediatric patients with B- 32 44 130
cell precursor ALL in first or second
complete remission with MRD ≥0.1%

July 2017

Relapsed or refractory B-cell
precursor ALL in adults and children

December
2014

Philadelphia chromosome-negative
130 132–134
relapsed or refractory B-cell precursor
ALL

Inotuzumab
ozogamicin

Anti-CD22
antibody–
drug
conjugate

Anti-CD22 antibody conjugated to a
August 2017 Adults with relapsed or refractory B-
DNA-damaging calicheamicin payload
cell precursor ALL
that causes apoptotic death

Tisagenlecleucel

CAR T cell
therapy

Genetically modified autologous T
cells expressing a chimeric receptor
consisting of a CD19-recognition
domain and 4-1BB costimulatory
domain to enhance expansion and
persistence

20 131

21 54 101

August 2017 Patients up to 25 years of age with
33 44
B-cell precursor ALL that is refractory
or in second or later relapse

CAR, chimeric antigen receptor; FDA, Food and Drug Administration; MRD, minimal/measurable residual disease.
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Table 4 Clinical trials using blinatumomab in ALL
Enrolled
patients

Primary
endpoint

Prospective, Adults with Ph− RR
TOWER
(NCT02013167) randomized B-ALL
phase III

405

ALCANTARA
Open-label-, Adults with Ph+ RR
(NCT02000427) single-arm
B-ALL
phase II

45

Trial

Study
design

Patient population

Results

Reference

OS

Median OS 7.7 months in
blinatumomab group versus
4.0 months in the chemotherapy
group (HR 0.71; 95% CI, 0.55 to
0.93; p=0.01)

20

CR or CRh

CR or CRh rate 36% (95% CI, 22%
to 51%) with 88% MRD−

135

MT103-205
Phase I/II
(NCT01471782)

Children with RR B-ALL 93 total (49 MTD (phase
phase I) (44 I) CR (phase
phase II)
II)

BLAST
Open-label,
(NCT01207388) single-arm
phase II

Adults with B-
ALL in first or later
hematological CR and
persistent or recurrent
MRD ≥10−3

113

Complete
MRD
response

CR rate 39% (95% CI, 27% to 51%) 136
with 52% MRD−
78% achieved MRD−

32

B-ALL, B-cell acute lymphoblastic leukemia; CR, complete response; CRh, CR with partial hematologic recovery; FDA, Food
and Drug Administration; MRD, minimal/measurable residual disease; MTD, maximum-tolerated dosage; OS, overall survival; Ph,
Philadelphia chromosome; RR, relapsed/refractory.

with RR diffuse large B-cell lymphoma, based on findings
from the pivotal JULIET study.40 Although immunotherapies in development are discussed in a separate section of
this manuscript, it’s important to acknowledge that with
84 active immunotherapy clinical trials for ALL registered
with the US National Library of Medicine in June 2020,
additional options will emerge every year.
Blinatumomab
Blinatumomab is a BiTE antibody construct that
directs CD3 positive T cells to CD19-
positive cells.
CD19 is expressed on blast cells in >95% of cases of
B-cell precursor ALL. Results from the landmark trials
leading to blinatumomab’s approval are described in
table 4.
Data from the phase III randomized clinical trial,
TOWER, demonstrated that blinatumomab increased
median OS compared with chemotherapy in patients
with heavily pretreated Philadelphia chromosome
negative (Ph−) B-
ALL.20 The median OS was 7.7
months in the blinatumomab group and 4.0 months
in the chemotherapy group (p=0.01). Remission
rates within 12 weeks after initiation of treatment
were significantly higher in the blinatumomab group
than in the chemotherapy group, both with respect
to CR with full hematological recovery (34% vs 16%;
p<0.001) and with respect to CR with full, partial,
or incomplete hematological recovery (44% vs 25%;
p<0.001). Treatment with blinatumomab resulted in
a higher rate of event-free survival (EFS) than that
with chemotherapy (6-month estimates, 31% vs 12%;
HR for an event of relapse after achieving a CR with
full, partial, or incomplete hematological recovery, or
death, 0.55; 95% CI, 0.43 to 0.71; p<0.001), as well as a
longer median remission duration (7.3 vs 4.6 months).

Based on data from these trials, the FDA granted full
approval to blinatumomab in July 2017 for patients
with RR B-ALL.31 Blinatumomab efficacy has also been
evaluated as a therapy for patients with B-ALL who are
in morphological remission after induction chemotherapy, but are positive for MRD. One hundred and
sixteen patients received blinatumomab. Eighty-eight
(78%) of 113 evaluable patients achieved a complete
MRD response. In the subgroup of 110 patients with
Ph– ALL in hematological remission, the relapse-
free survival (RFS) at 18 months was 54%. Median
OS was 36.5 months. In landmark analyses, complete
MRD responders had longer median RFS (23.6 vs
5.7 months; p=0.002) and OS (38.9 vs 12.5 months;
p=0.002) compared with MRD non-responders.32 41 On
March 29, 2018, the FDA approved blinatumomab for
patients with B-ALL with positive MRD.31
Inotuzumab ozogamicin
Inotuzumab ozogamicin is a humanized anti-
CD22
monoclonal antibody conjugated to calicheamicin, a
cytotoxic antibiotic agent. After the conjugate binds
to CD22, the CD22-conjugate complex is rapidly internalized, and calicheamicin is released. Calicheamicin
binds to the minor groove of DNA and induces double-
strand breaks and subsequent apoptosis (table 3).42
The FDA approved inotuzumab ozogamicin on
August 17, 2017 for the treatment of patients with RR
B-ALL.43 In the phase III INO-VATE trial, 109 patients
with RR B-ALL, regardless of Philadelphia chromosome status, received inotuzumab ozogamicin. CR was
achieved in 80.7% of patients who were treated with
inotuzumab ozogamicin (95% CI, 72.1% to 87.7%)
compared with 29.4% of patients (n=109) who were
treated with standard-
of-
care (SOC) chemotherapy
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(95% CI, 21.0% to 38.8%; p<0.001). Median OS for
inotuzumab ozogamicin was 7.7 months (95% CI, 6.0%
to 9.2%) versus 6.7 (95% CI, 4.9% to 8.3%) months
for standard care; the 2-year OS rates were 23% (95%
CI, 16% to 30%) versus 10% (95% CI, 5% to 16%),
respectively. The primary objective to demonstrate
significantly improved final OS with inotuzumab
ozogamicin compared with standard care was not
met. An exploratory post hoc restricted mean survival
time analysis was applied to more precisely define the
clinical benefit of inotuzumab ozogamicin. In this
analysis, mean overall survival was longer in the inotuzumab ozogamicin group than in the standard-therapy
group (mean [±SE], 13.9±1.10 months versus 9.9±0.85
months; p=0.005).21
Tisagenlecleucel
Tisagenlecleucel is an anti-CD19 CAR T cell therapy,
generated via the ex vivo genetic engineering and
expansion of T lymphocytes obtained from the
patient’s blood to incorporate a novel receptor into
the T cell repertoire. Engineered T cells recognize
and associate with antigen-positive malignant cells for
elimination. In the phase I/IIa ELIANA trial, 75 children and young adults (median age: 11 years, range: 3
to 23 years) with RR B-ALL were treated with tisagenlecleucel. Of the enrolled patients, 46 (61%) had undergone prior allo-HCT. Before tisagenlecleucel infusion,
72 of 75 patients (96%) received lymphodepleting
chemotherapy. The overall remission rate was 81%
(95% CI, 71% to 89%); 45 patients (60%) had CR,
and 16 (21%) had CR with incomplete hematologic
recovery (CRi). All patients who had a best overall
response of CR with or without complete hematologic
recovery were negative for minimal residual disease;
95% (58 of 61) of these patients were negative by
day 28. The median duration of follow-
up among
patients who received a tisagenlecleucel infusion was
13.1 months. The rates of EFS and OS were 73% (95%
CI, 60% to 82%) and 90% (95% CI, 81% to 95%),
respectively, at 6 months and 50% (95% CI, 35% to
64%) and 76% (95% CI, 63% to 86%) at 12 months.33
On August 30, 2017, tisagenlecleucel became the
first ever FDA-
approved CAR T therapy, gaining
approval for the treatment of patients ≤25 years of age
with B-ALL who have relapsed or have not responded
after two previous lines of therapy.44 Approval was
based on data from 63 patients, and among the infused
patients, 52 (83%) achieved CR/CRi, all of which were
MRD negative. Recently presented data suggest that
responses to anti-
CD19 CAR T therapy are exceptionally durable. Follow-up analyses from 97 patients
enrolled in the ELIANA trial demonstrate 18-month
RFS of 66% (95% CI, 52% to 77%) and 18-month OS
probability of 70% (95% CI, 58% to 79%) with median
OS not yet reached at the time of analysis.45
It is of note that the current FDA approval for tisagenlecleucel does not include adult patients with ALL aged 26
6

years or older.46 As such, clinical trials investigating anti-
CD19 CAR T cell therapy for the treatment of older adult
patients with ALL are underway. Approval for this treatment modality for adult patients with ALL is anticipated
in the near future.
MRD status
Measurable residual disease (MRD) has been used to
identify CR patients at a high risk of relapse. MRD is
defined as the post-therapy persistence of leukemic
cells at levels below morphological detection in the
bone marrow or peripheral blood. MRD status of
patients is considered a risk factor for relapse and is
often used to select the next appropriate strategy for
previously treated patients with acute leukemia. Blinatumomab is the only FDA approved immunotherapy
in the ALL MRD positive disease setting at the time of
guideline preparation.31
The role of MRD in treatment decisions for ALL
remains an active area of investigation. Outcomes
are generally poor for patients with detectable MRD
at the time of allo-
HCT.34 47 However, the prognostic utility of MRD may vary depending on the
assay used for measurement. MRD may be assessed
by several methods including multicolor flow cytometry (MFC), PCR, and next-
generation sequencing
(NGS). Although flow cytometry is typically considered the gold standard, molecular methods that identify leukemic cells with high sensitivity are also used
in ALL.48 Studies are ongoing to determine whether
detection of leukemic DNA above a certain threshold
may consistently predict relapse after therapy. Newer
sequencing methods may offer more robust predictive
power. NGS-MRD predicted relapse and survival more
accurately than MFC-
MRD (p<0.0001), especially
in the MRD-negative patients (relapse, 0% vs 16%;
p=0.02; 2-year OS, 96% vs 77%; p=0.003). Post-HCT
NGS-MRD detection was better at predicting relapse
than MFC-MRD (p<0.0001), especially early after HCT
(day 30 MFC-MRD positive relapse rate, 35%; NGS-
MRD positive relapse rate, 67%; p=0.004).49 Ongoing
studies are evaluating how best to incorporate NGS-
based testing into patient care, especially in relation
to allo-HCT.
Results of a large meta-analysis of 13,637 patients with ALL
treated mainly with chemotherapy indicate that increased
EFS significantly correlates with the presence of MRD-
negative disease after treatment in both children and adults
(pediatric: HR=0.23; 95% Bayesian CI (BCI): 0.18 to 0.28;
adult: HR=0.28; 95% BCI, 0.24 to 0.33).36 Adults who were
MRD-negative had EFS of approximately 64% at 10 years
versus only 21% for those who were MRD-positive. The relative benefit in EFS of having achieved MRD negativity was
comparable in both age groups.
Among patients receiving CAR T therapy, a subset who
achieve MRD-
negative status experience durable remissions that persist with no further treatment.50 51 Although
the factors that favor durable remission after achieving
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MRD-negative status are under investigation, in one study
with patients treated with CAR T cells, the EFS and OS
were significantly better in the patients who achieved MRD-
negative CR compared with those who did not (median EFS
7.6 vs 0.8 months; p<0.0001; median OS 20.0 vs 5.0 months;
p=0.014). Patients achieving MRD-negative CR showed that
lower prelymphodepletion LDH concentration, higher
prelymphodepletion platelet count, incorporation of fludarabine into the lymphodepletion regimen, and allo-HCT after
CAR T cell therapy were associated with better EFS.50
Combination of allogeneic cell transplantation with
immunotherapy
Guidelines concerning indications for allo-HCT have been
generated by other societies and are outside the scope
of this manuscript.26 52 However, it is important to address
the role of allo-HCT and current immunotherapies, especially as more agents receive FDA approvals. Several publications have discussed the application of immunotherapy
both before and after allo-HCT. Relapse after HCT is associated with a very poor prognosis, yet immunotherapies
may improve outcomes. Although further trials are needed,
donor-
derived CD19-
targeted T cell infusions have been
evaluated for relapsed B-ALL after haplo-HCT.53 Additionally, trials assessing tisagenlecleucel (ELIANA) and blinatumomab (TOWER) included patients with B-ALL who had
relapsed following prior allo-HCT. Both agents were effective
and, importantly, tisagenlecleucel treatment did not result
in new episodes of graft-
versus-
host disease (GVHD).20 33
Inotuzumab ozogamicin and blinatumomab are both under
investigation as salvage regimens after HCT. Importantly,
inotuzumab ozogamicin carries a black-
box warning for
hepatotoxicity, including fatal and life-threatening sinusoidal
obstruction syndrome (SOS)/veno-occlusive disease (VOD)
in patients undergoing HCT after treatment.54
Allo-HCT after CAR T cell treatment has also been evaluated in clinical trials as a consolidation therapy to prevent
relapse. In the ELIANA trial, eight patients while in reemission received allo-HCT after tisagenlecleucel.45
In a separate trial, among 44 patients who had a CR after
the infusion of CAR T cells, 26 (59%) were observed who
had no further therapy and 17 patients (39%) proceeded
to transplantation. The median time from the CAR T cell
infusion to transplantation was 74 days (range, 44 to 312).
Of the 17 patients who underwent allo-HCT after the CAR
T cell infusion, 5 patients were alive and had CRs, 6 had
relapses, and 6 died from transplant-related toxic effects.
Among the 32 patients who had a MRD-
negative CRs,
there was no significant difference in EFS and OS between
patients who underwent transplantation and those who
did not (p=0.64 for EFS and p=0.89 for OS by the log-rank
test).55
Concerns have been raised about the use of checkpoint
inhibitors prior to or after allo-HCT. While checkpoint inhibition may augment the graft-versus-tumor effect, immune
activation may place patients at risk of GVHD.56 57 The
timing of administration may also play a role in determining
the safety of checkpoint inhibition in a treatment plan that

includes transplant. A review of 24 studies encompassing
283 patients with a variety of hematological malignancies
including 28 patients with AML and 4 patients with ALL
found that the incidence of acute GVHD among patients
receiving checkpoint inhibitor therapy prior to allo-HCT was
56%, and 29% of patients developed chronic GVHD. There
was a trend toward higher incidences of GVHD in patients
with shorter median intervals between receiving the last dose
of checkpoint inhibitor therapy and allo-
HCT compared
with patients having longer intervals.57 The duration during
which GVHD risk may be increased by persistent immune
activation induced by checkpoint inhibition in patients with
leukemia is not currently known.
Panel recommendations
►► While a number of immunotherapies do have a role in
the treatment of patients with acute leukemia in various
settings, clinical trial enrollment should be considered at
each juncture.
►► New, experimental drugs should be administered at
centers that have proper support, infrastructure, and
subspecialties.
►► Patients with relapsed B-
ALL should receive immunotherapy as a bridging therapy to induce remission
prior to allo-HCT.
►► Options for patients with relapsed ALL after one line
of prior therapy include clinical trial enrollment, treatment with blinatumomab or inotuzumab ozogamicin, or
allo-HCT.
►► For patients with relapsed B-
ALL and a high disease
burden, inotuzumab ozogamicin should be considered
first followed by blinatumomab for persistent disease
or MRD positivity, based on the clinical experience and
consensus of the Expert Panel.
►► Because inotuzumab ozogamicin increases the risk of
SOS/VOD in subsequent transplants, the number of
cycles should be limited if allo-HCT is planned.
►► Patients with newly diagnosed B-
ALL who are MRD
positive after undergoing induction chemotherapy
should be offered blinatumomab.
►► CAR T cell therapy is strongly recommended for
patients with relapsed ALL after second-line and/or
third-line therapy.
►► Outcomes for MRD‐positive patients are generally poor;
therefore, enrollment into a clinical trial should be
considered to help achieve an MRD‐negative status.
IMMUNOTHERAPY FOR THE TREATMENT OF PATIENTS WITH
AML
To date, relatively few immunotherapy approaches have
been approved for the treatment of patients with AML
compared with those available for the treatment of
patients with ALL, although many are in clinical trials and
some show promising preliminary results. One possible
cause for this discrepancy is the difficulty in identifying
targetable antigens on myeloid cells that allow for safe
anticancer activity with defined long-term effects on the
patient. Currently, the only approved immunotherapeutic
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strategies for treating AML are allo-HCT and the CD33-
targeting ADC GO. However, several research programs
and clinical trials are currently underway hoping to
further the repertoire of therapies such as checkpoint
inhibitors, unconjugated antibodies, BiTEs, and CAR T
cell therapies in the treatment of AML.
Approved agents and indications
Gemtuzumab ozogamicin
GO, an anti-CD33 ADC, using a calicheamicin-derivative
cytotoxic drug, was the first ADC approved for human use
by the FDA for AML. On binding to CD33, GO is rapidly
internalized, leading to the intracellular release of calicheamicin, a potent DNA-
damaging agent that causes
single-strand and double-strand breaks, which leads to
checkpoint activation, cell cycle arrest, and the activation of cell death pathways.58 GO was granted accelerated approval in the USA in 2000 for patients aged 60
years or older with CD33-positive AML in first relapse and
who are not considered to be candidates for cytotoxic
chemotherapy. Accelerated approval was granted after
promising results from a single phase I study and three
phase II trials, where the overall response rate (ORR) was
30% in a total of 142 patients.59 After the initial approval,
however, GO was increasingly recognized to be associated
with hepatotoxicity and severe SOS,60 leading the FDA
to issue a black-box warning. The drug was voluntarily
withdrawn in 2010 after a postapproval phase III clinical
trial that found an increase in treatment-related mortality
with no improvement in CR rate, disease-free survival, or
overall survival (OS), with the addition of GO to standard
induction or postconsolidation therapies.61
However, recently, GO has reemerged as an option for
the treatment of AML. In 2017, GO was reapproved for
the treatment of newly diagnosed CD33-
positive AML

in adults (both alone or in combination with induction
chemotherapy) and as a single agent for the treatment of
RR CD33-positive AML in adults and in pediatric patients
aged 2 years and older.30 The studies leading to reapproval are summarized in table 5. Additionally, a 2014
meta-analysis of five trials encompassing 3325 patients
found that the addition of GO to induction chemotherapy significantly reduced the risk of relapse (OR
0.81; p=0.0001) and improved OS at 5 years (OR 0.90;
p=0.01).62
The current FDA approval indicates GO as both a single
agent and in combination with chemotherapy during
induction and consolidation for newly diagnosed AML in
adults and in pediatric patients aged 1 month and older.
In the RR setting, GO is approved for adult patients and
is used as a monotherapy.30
MRD status
The importance of the MRD status of patients has also
been investigated in AML settings. Several strategies
exist to assess MRD status, including MFC, qRT PCR, and
NGS.25 In one study of 482 patients aged 18 to 65 years
with newly diagnosed AML, molecular MRD status determined via NGS correlated with risk of relapse in patients
who achieved CR after induction therapy.35 The detection of molecular MRD was associated with a significantly
higher relapse rate than no detection (55.4% vs. 31.9%;
HR, 2.14; p<0.001), as well as with lower rates of RFS
(36.6% vs. 58.1%; HR for relapse or death, 1.92; p<0.001)
and OS (41.9% vs. 66.1%; HR for death, 2.06; p<0.001).
In a meta-analysis, pretransplant MRD was associated with
worse leukemia-free survival (HR=2.76; 95% CI, 1.90 to
4.00), (OS HR=2.36; 95% CI, 1.73 to 3.22), and cumulative incidence of relapse (HR=3.65; 95% CI, 2.53 to 5.27),
but not non-relapse mortality (HR=1.12; 95% CI (0.81

Table 5 Clinical trials using GO in AML
Enrolled
patients

Primary
endpoint

Patients aged 50–70 years
with de novo AML

280

Randomized
phase III

Patients aged 61 years or
older with de novo AML
unsuitable for intensive
chemotherapy

Mylo-France 1

Single-arm,
open label
phase II

AAML0531

Multicenter
randomized
phase III

Trial

Study design

Patient population

Results

Reference

ALFA-0701

Randomized
phase III

EFS

GO arm, median 17.3 months
vs control arm, median 9.5
months; p=0.0002

137 138

EORTC-
GIMEMA AML19

237

OS

Median OS 4.9 months vs
3.6 months (HR, 0.69; 95% CI,
0.53 to 0.90; p=0.005)

139

Patients aged 18 years or
older with RR AML

57

CRR

CRR 26% and 7% CR with
incomplete platelet recovery

140

Patients aged 0 to 29 years
with newly diagnosed AML

1022

EFS,OS

GO+chemotherapy improved
EFS (3 years: 53.1% v
46.9%, p=0.04) OS, 3 years:
69.4% v 65.4%,p=0.39
GO+chemotherapy versus
chemotherapy alone

141

AML, acute myeloid leukemia; CR, complete response; CRR, complete response rate; EFS, event-free survival; GO, Gemtuzumab
ozogamicin; OS, overall survival; RR, relapsed/refractory.
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to 1.55). These associations held regardless of detection
method, conditioning intensity, and patient age.63
Combination of allogeneic cell transplantation with immunotherapy
Immunotherapies for the treatment of AML remain an
ongoing subject of research, and data on the optimal integration of these novel agents into established approaches
are limited. Given that graft-versus-leukemia effects are
an important contributor to outcomes after allo-HCT,10–12
caution is warranted when incorporating any immune-
targeting modality into a treatment plan that includes
transplant. One phase I/Ib clinical trial assessing the anti-
cytotoxic T-
lymphocyte-
associated protein 4 (CTLA-4)
checkpoint inhibitor ipilimumab after allo-
HCT in
patients with relapsed hematological malignancies—
including 12 patients with AML—observed 1 year OS
of 49% with 14% of total patients (4/28) developing
GVHD.56 Another phase I study demonstrated that pediatric patients with AML who received reduced-intensity
conditioning allo-HCT followed by consolidation therapy
involving GO had a probability of developing grades II to
IV acute and chronic GVHD of 21% and 33.5%, respectively. Probability of OS after allo-HCT and GO consolidation at 1 and 5 years was 78% and 61%, respectively.
Probability of 5-year EFS after allo-HCT and GO consolidation in patients in CR1 was 78%.64
Although FDA-
approved immunotherapies have
demonstrated enhanced curative potential compared
with standard treatment modalities, several patients will
not respond or will relapse after immunotherapy-induced
remissions. The pathophysiology of AML postrelapse
remains an ongoing and important area of study. Deregulation of pathways involved in T cell-mediated allorecognition has been identified as a feature and driver of AML
relapses after allo-
HCT,65 including downregulation of
major histocompatibility complex class II genes involved
in antigen presentation, loss of HLA class I antigens in
the case of HLA-matched and HLA-mismatched transplants, and the acquisition of de novo mutations.66–68
These changes potentially offer insights that could eventually be translated into personalized therapies.
Relapse after allo-HCT in AML is generally associated
with a very poor prognosis without active treatment.
Remission may be achieved through the administration of
donor lymphocyte infusion (DLI). A retrospective, analysis of 399 patients with AML in first hematological relapse
after allo-HCT estimated that DLI prolonged survival rates
at 2 years to 21%±3% compared with 9%±2% for patients
not receiving DLI.69 The use of DNA methyltransferase
inhibitors (DNMTs; azacitidine, Aza; or decitabine, DAC)
have been used in conjunction with DLI to induce antileukemia CD8+ T cell responses by enhancing the expression
of epigenetically silenced tumor antigens. The prospective multicenter AZARELA trial reported encouraging
ORRs for Aza+DLI treatment after relapse, including five
patients continuing CR for a median of 777 days without
any additional treatment. The incidence of acute and
chronic GVHD was 37% and 17%, respectively, and all

cases were mild.70 Several other studies have demonstrated similar benefits with DNMTs, with or without DLI,
for relapsed patients after allo-HCT.69 71–73 It is currently
not known whether DLI combined with DNMTs is more
effective than either therapy alone. Ongoing studies are
evaluating strategies to enhance response rates for DLI
post-transplant, including in combination with immunomodulatory agents.
Panel recommendations
►► While many immunotherapy approaches may have a
role in the treatment of patients with AML in various
settings, clinical trial enrollment should be considered at each juncture.
►► GO may be added in favorable and possibly
intermediate-risk patients with AML during induction
chemotherapy.
►► GO should be considered at the time of AML relapse
and in newly diagnosed patients with AML who are not
eligible to receive intensive induction chemotherapy.
►► Outcomes are generally worse after allo-
HCT for
patients who achieve morphological remission after
induction chemotherapy, yet display persistent MRD.
Further studies are needed to identify therapeutic
options for these patients. Therefore, enrollment into
a clinical trial should be considered to help achieve an
MRD‐negative status.
EMERGING IMMUNOTHERAPIES FOR THE TREATMENT OF
PATIENTS WITH ACUTE LEUKEMIA
A number of novel agents and strategies are being tested
in preclinical and clinical settings. Promising results have
been reported for both antibody-based and cell-based therapies, especially in the rapidly burgeoning CAR T cell field.
As novel immunotherapies demonstrate safety and efficacy
in clinical trials, more options will emerge for practicing
clinicians. Because many of these agents have not yet been
approved by the FDA, the committee emphasizes that new
experimental drugs should only be administered at centers
with proper support, infrastructure, and subspecialties in
place to monitor outcomes and adverse events (AEs).
Agents and indications
Rituximab
Rituximab, a chimeric anti-CD20 antibody, has been evaluated with combination chemotherapy for patients with
B-ALL demonstrating improved EFS as well as OS benefit
and molecular CR rates (table 6).15 74 Although rituximab
is not FDA approved for the treatment of CD20+ ALL,
rituximab is being used in combination with ALL chemotherapeutic regimens during induction, consolidation,
and maintenance therapies.
Bispecific cell engager therapies
Based on the success of blinatumomab in ALL, efforts
are underway to develop similar agents targeting antigens specific for AML, such as CD123 and CD33.75 Additional studies for bispecific cell engagers targeting the
leukemic cell antigen CD33 are ongoing. A phase I study
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Table 6 Studies evaluating rituximab in ALL
Patient
population

Enrolled
patients

Endpoints

Adults with
CD20+, Ph−
B-ALL

209

EFS

Thomas et al, Prospective,
Adolescents
JCO 2010
non-randomized and adults
with de novo
Ph− B-ALL

282

Trial

Study design

GRAAL

Randomized
phase III

Results

Reference

65% with rituximab (95% CI, 56% to
15
75%) versus 52% with standard of
care (95% CI, 43% to 63%); HR=0.66;
(95% CI, 0.45 to 0.98; p=0.04)
74
CR rate;
In the younger (age <60 years) CD20-
3-year CRD positive subset, rates of CRD and OS
rate; OS
were superior with the modified hyper-
rate
CVAD and rituximab regimens compared
with standard hyper-CVAD (70% v 38%;
p<.001% and 75% v 47%, p=.003).
Older patients with CD20-positive ALL
did not benefit from rituximab-based
chemoimmunotherapy

ALL, acute lymphoblastic leukemia; B-ALL, B-cell acute lymphoblastic leukemia; CR, complete response; CRD, CR duration; CVAD,
fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; EFS, event-free survival; OS, overall survival; Ph, Philadelphia
chromosome.

of the CD33/CD3 BiTE AMG330 demonstrated acceptable safety profiles in 35 patients with RR AML.76 Studies
are also ongoing for another CD33/CD3 bispecific cell
engager, AMV564, which demonstrated safety and antileukemia activity in a first-in-human trial in patients with
RR AML.77
A study evaluating a trispecific killer engager (TriKE)
therapy engaging CD16 on natural killer (NK) cells and
targeting CD33 on AML/MDS with an interleukin (IL)-15
linker between the two domains has just been opened for
accrual in AML (NCT03214666). The drug differs from
bispecific cell engagers due to the NK cell activation it
provides while bringing them in proximity to malignant
blasts due to the presence of the IL-15 linker domain. At
the time of publication, the single-center phase I/II clinical trial is enrolling patients with refractory AML defined
as failure to achieve remission after at least three induction attempts or relapsed AML who are not a candidate
for HCT after at least one re-induction attempt, as well as
patients with prior HCT relapse beyond 3 months without
active GVHD.
Antibody–drug conjugates
Based on extremely promising preclinical data, several
ADCs targeting different surface markers and carrying
different payloads have begun making their way through
clinical trials. Initial results from the ongoing SIERRA
study (NCT02665065) have indicated safety and feasibility
for Iomab-B, an anti-CD45 ADC-carrying radioactive 131I,
as a bridging therapy before transplant for patients with
RR AML. Analysis of the first 25% of enrolled patients
(n=38) showed a rapid reduction in the leukemia burden
after Iomab-B treatment, setting the stage for successful
engraftment after allo-HCT.78 Another ADC, IMGN632,
a CD123-
targeting antibody linked to a novel DNA-
alkylating agent, has demonstrated in an ongoing phase
I study objective responses in RR AML, including 1 CR
10

and 3 CRi, with no dose-limiting toxicities.79 Additionally,
the CD30-specific ADC brentuximab vedotin has demonstrated favorable safety in a phase I trial (NCT01830777)
when administered in combination with a conventional
mitoxantrone, etoposide, and cytarabine reinduction chemotherapy regimen for patients with CD30+
RR AML.80
Checkpoint inhibitors
To date, immune checkpoint inhibitors, which have
demonstrated efficacy for treating patients with solid
tumors and classical Hodgkin lymphoma, have not had
similar significant success in acute leukemias. Ongoing
studies are evaluating the combination of checkpoint
inhibition with blinatumomab for B-ALL, and one phase
I study reported an MRD-negative CR rate of 80% in
five heavily pretreated patients with a significant baseline disease burden.81 Checkpoint inhibitors remain
under investigation as single agents for maintenance
following allo-
HCT, especially in the context of AML,
where some studies indicate that checkpoint inhibition
augments the graft-versus-leukemia effect as well as in
combination regimens with chemotherapy. Combinations of nivolumab (an anti-PD-1 antibody), in combination with hypomethylating agents (HMAs) or induction
chemotherapy have recently been reported.82–84 In one
example, patients with RR AML received nivolumab with
azacitidine. The overall response rate (ORR) was 33%
including 15 (22%) CR/CRi, 1 partial response (PR), and
7 patients with hematological improvement maintained
for 6 months or longer. The ORR was 58% and 22%, in
HMA-naive (n=25) and HMA pretreated (n=45) patients,
respectively.82 In another example, patients with RR AML
received pembrolizumab following high-dose cytarabine.
The ORR of 10 evaluable patients was 50%, with 4 CR/
CRi.85 Other promising results emerged from a phase II
trial evaluating a triplet regimen combining nivolumab
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with ipilimumab and azacitidine, with a CR/CRi rate of
36% and a 1-year survival rate of 45% in a cohort of 31
patients with RR AML.86 These, and several other studies,
are currently ongoing.
CAR T cell therapies
Bolstered by the success of CD19 targeting CAR T
cell therapies in the pediatric B-ALL setting, ongoing
research is evaluating novel agents for patients with ALL,
new approaches that can provide adult patients with
ALL access to CAR T cell treatment, and strategies for
the treatment of patients with AML. Several studies are
working to develop CAR T cell therapies targeting non-
CD19 antigens for patients with CD19-negative disease or
for those who relapse after anti-CD19 CAR T cell infusion. Among the most mature are CD22-directed CAR T
cells for the treatment of RR B-ALL. Fry and colleagues
reported initial results from a phase I trial testing a new
CD22-targeted CAR in 21 children and adults, including
17 who were previously treated with CD19-directed immunotherapy. Dose-
dependent antileukemic activity was
observed, with CR obtained in 73% (11/15) of patients
receiving ≥1×106 CD22-CAR T cells per kilogram body
weight, including in five out of five patients with CD19dim
or CD19-negative B-ALL. Median remission duration was
6 months. Relapses were associated with diminished CD22
site density that likely permitted CD22+ cell escape from
killing by CD22-CAR T cells.28 A follow-up report on that
trial included 52 patients. 36 patients (69.2%) had undergone HCT; 30 (57.7%) had prior CD19 CAR; 22 (42.3%)
had prior blinatumomab; and 28 (53.8%) subjects had
a CD19-
negative population, including 2 who were
inherently partial CD19 -negative without prior targeted
therapy. The CR rate was 72.5% overall; 84% at the
current dose level. This included CRs seen in subjects who
were non-responders to CD19 CAR T cell therapy and/or
blinatumomab. The longest remission was >3 years (n=1)
post-CAR T cell infusion. Relapse occurred at a median
of 6 months postinfusion in 23 (64%) subjects primarily
due to CD22 modulation. Twelve patients proceeded to
HCT following CD22 CAR T cell therapy.87 Another study
in 34 pediatric and adult patients with RR B-ALL who did
not respond from previous CD19 CAR T cell therapy were
treated with CD22 CAR T cell therapy found that CR or
CRi was achieved in 24 of 30 patients (80%) that could be
evaluated on day 30 after infusion, which accounted for
70.5% of all 34 enrolled patients.88
CAR T cell therapies for the treatment of patients
with AML are also in development. One promising
strategy currently being assessed in multiple clinical
trials involves CAR T cell therapies that target CD33 on
myeloid cells. Anti-CD123 CAR T cell therapies for the
treatment of patients with RR AML are also being evaluated.89 Other clinical trials are ongoing, including CAR
T cells targeted against CD7 (NCT04033302) and FLT3
(NCT03904069).

Other cell therapies
Beyond CAR T cells, several other immune effector
cell-
based therapies are undergoing evaluation. One
approach involves the infusion of donor lymphocytes
genetically engineered to express the herpes simplex
virus thymidine kinase (the so-
called “suicide gene”)
after haploidentical HCT.90 Other studies are evaluating
additional strategies, including infusion of T regulatory
type 1 cells after HCT as well as personalized NK cell
therapy after chemotherapy, and umbilical cord blood
transplant.
Advances have been made in cytokine-induced NK cell
therapy as well as in the infusion of autologous T cells
specific for WT1 for AML. A first-in-human phase I clinical
trial demonstrated that adoptively transferred allogeneic
NK cells induced to a memory-like phenotype through
preincubation with IL-12, IL-15, and IL-18 proliferated
and expanded in patients with AML and demonstrated
robust responses against leukemia targets.91 Donor-
derived WT1-specific CD8+ cytotoxic T cells have demonstrated direct evidence of antileukemic activity92 and
prophylactic infusion of Epstein-Barr virus-specific donor
CD8+ T cells transduced with a T cell receptor specific
for WT1 post-HCT was associated with 100% RFS in 12
patients with a median follow-up of 44 months, while a
concurrent comparative group of 88 patients with similar
risk AML had 54% RFS (p=0.002).93
As personalized cell therapy requires several weeks of
production, there is a growing interest in off-the-shelf
NK cell products. One way to accomplish this goal is by
differentiation of induced pluripotent stem cells (iPSC)
into an unlimited supply of cryopreserved NK cells for
immediate availability and allowing for multidose strategies.94 One example of this strategy, FT516, which consists
of iPSC-derived NK cells engineered with a high-affinity,
non-cleavable CD16 Fc receptor, has entered phase I/Ib
clinical trials in patients with primary refractory AML and
relapsed AML (NCT04023071).
Panel recommendations
Patients should be treated with FDA-approved therapies, if available, with clinical trial enrollment considered at each juncture.
►► New, experimental drugs should be administered
at prepared institutions. Institutions need to have
proper support, infrastructure, and subspecialties.
►► The use of rituximab in patients with CD20+ B-ALL is
recommended.
►►

ROLE OF IMMUNOTHERAPY POST-CAR T CELL THERAPY
CAR T cell therapies have offered significant survival benefits for patients with ALL and data suggest that responses
are durable. In some cases, however, CAR T cell therapy is
ineffective due to either lack of the targetable antigen or
antigen loss after initial therapy. Therefore, many novel
CAR T cell therapies are under investigation to provide
secondary options for these patients. In some cases, other
immunotherapeutics may be options for patients who
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have relapsed or are refractory to FDA-approved CAR T
cell therapies.
Although trials are underway for tisangenlecleucel as
treatment for pediatric and young adult patients with
B-ALL who received first-line treatment and are MRD
positive at the end of consolidation therapy (CASSIOPEIA, NCT03876769), the current FDA approval is
for refractory patients or in patients in second relapse
or later. Relapse after CAR T cell therapy is sometimes
due to the loss of the target antigen.28 45 The prognosis
of patients who relapse post-CAR T cell administration
is often considered poor, especially considering that the
anti-CD19 blinatumomab is also rendered ineffective in
patients with CD19 loss.
The availability of multiple CD19-targeting therapies
including BiTEs and CAR T cells makes decisions on
optimal treatment sequencing challenging, especially
given the possibility for relapse mediated by antigen loss.95
Options for patients who relapse post-CAR T cell therapy
include salvage chemotherapy, clinical trial enrollment,
allo-HCT, or retreatment with CAR T cells (potentially
targeting different antigens, depending on the mechanism of relapse). Allo-HCT transplant is potentially an
option for patients who relapse after CAR T cell therapy,
but these patients are often ineligible for transplant.
There are multiple studies investigating CAR T cell
therapies that target antigens other than CD19 for the
treatment of patients with CD19-
negative ALL. There
have been encouraging reports of therapeutic response
in patients who have relapsed after CD19-targeted CAR
T-cell therapy. For example, one study notes that patients
with CD19-negative B-ALL displayed a median remission
duration of 6 months after receiving anti-CD22 CAR T
cell therapy. Of note, relapse due to loss of CD22 was also
observed in this trial.28 As such, there are clinical studies
investigating bispecific CAR T cell therapies that target two
antigens concurrently to increase efficacy and reduce the
risk of relapse.96 In one phase 1 trial of bispecific CD19/
CD22 CAR T cells, CR was achieved in 5/7 (71%) RR
ALL patients by day 21, 4 of which were minimal residual
disease negative. Therapy was well tolerated with no dose
limiting toxicities. CRS occurred in 5 subjects (Grade 1)
with 2 of these subjects experiencing mild neurotoxicity.
(Grade 1).97 Another study of the CD19/CD22 ‘cocktail
CAR T cell’ approach for RR B-ALL demonstrated a 100%
CR/CRi rate on day 20 to 30 after infusion in 15 patients
with 14/15 (93.3%) achieving MRD negativity.98 A very
low treatment-related toxicity was observed in this trial.
Only 1 patient experienced grade 3 CRS and another
patient (6.7%) developed grade 3 central nervous system
toxicity; all other patients were CRS grade<2 and CNS
grade 0.
Panel recommendations
►► With very few options available to patients who relapse
after CAR T cell therapy, clinical trial enrollment
should be strongly considered.
12

►►

For patients with ALL who relapse or are refractory to
CAR T cell therapy, a consensus could not be reached
to recommend one preferred treatment. Potential
options could include CAR T cell therapy targeting
different antigens, blinatumomab, or allo-
HCT (if
eligible).

RECOGNITION AND MANAGEMENT OF IMMUNE-RELATED AES
IN PATIENTS WITH ACUTE LEUKEMIA BEING TREATED WITH
IMMUNOTHERAPY
Immune-related AEs are of significant concern in the field
of immuno-oncology. Immunotherapies have distinct and
significant toxicities requiring skilled management. SITC
has published a textbook guide to managing immunotherapy toxicity as well as a consensus statement from
the Toxicity Management Working Group concerning
the management of toxicities after treatment with checkpoint inhibitors.99 Toxicity management after CAR T cell
therapy for hematological malignancies is described in
a 2018 review publication from SITC.17 At the time of
publication, two additional SITC clinical practice guidelines for the recognition and management of immune-
related AEs for immune effector cell and checkpoint
inhibitor therapies are in preparation. Additionally, the
American Society for Transplant and Cellular Therapy
has published consensus guidelines for grading CRS and
neurological toxicity after CAR T cell therapy.100
AEs arising during treatment for ALL with immunotherapy are distinctive and must be recognized early and
managed appropriately. Concerning inotuzumab ozogamicin, 46% of patients treated with inotuzumab ozogamicin in the INO-VATE trial experienced ≥grade 3 AEs,
similar to the rate and profile of ≥grade 3 AEs in patients
who received SOC chemotherapy (43%). VOD occurred
more frequently in the inotuzumab ozogamicin group
than in the standard-therapy group (in 11% (15 patients)
vs 1% (1 patient)). Of the 48 patients in the inotuzumab
ozogamicin group who underwent stem cell transplantation after the trial, 10 had VOD after transplantation. The
median time to the development of VOD associated with
transplantation in the inotuzumab ozogamicin group was
16 days (range, 3 to 39 days).21 Recent consensus recommendations for the prevention and monitoring of VOD
associated with inotuzumab ozogamicin include: avoid
HCT conditioning regimens containing dual alkylating
agents, use prophylactic medicines in patients proceeding
to HCT, limit treatment with inotuzumab ozogamicin to
2 cycles, monitor patient weight for fluid retention, and
frequently assess liver function.101
Both blinatumomab and CAR T cell therapies can result
in serious AEs including CRS and neurotoxicities.102 103
These two events can be fatal if not properly managed.
CRS was the most common AE reported across all CAR
T cell clinical trials, with an incidence as high as 74% to
100% for CD19-directed CAR T cells.33 103–105 CRS can
present with a variety of symptoms. Mild symptoms of CRS
include fever, headache, rash, arthralgia, and myalgia.
More severe cases are characterized by hypotension that
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can progress to an uncontrolled systemic inflammatory
response with vasopressor-
requiring circulatory shock,
vascular leakage, disseminated intravascular coagulation,
and multiorgan system failure.100 103 106–112
Several descriptions of management strategies for CAR
T cell-associated CRS have been published, which generally encompass supportive care and anti-IL-6 therapies to
break the cycle of inflammation.103 109 110 113–115 110 CRS
toxicity may be mitigated by modifying the dosing of CAR
T cells to attenuate peak expansion and proliferation, as
was demonstrated in a recent report using fractionated
dosing scheme of infused CAR T cells that demonstrated
high response rates with acceptable tolerability in adult
patients with ALL.116
Neurotoxicity has been reported in nearly every study
involving CD19-directed T cells, including CAR T cells
and blinatumomab. In the TOWER trial evaluating
blinatumomab for the treatment of patients with ALL,
25/267 (9.4%) patients experienced neurotoxicities.20
Neurotoxicities were also observed in the ELIANA trial of
tisagenlecleucel, where 40% of patients (30/75) experienced an event of any grade, and 13% of patients (10/75)
experienced a grade 3 event.33 Risk factors for neurotoxicity after CAR T cell treatment include extramedullary
disease younger age, pre-existing neurological comorbidities, higher total CAR T cell doses, early and/or severe
CRS, and cytopenias.114 117 Unlike CRS, neurotoxicity
secondary to CAR T cell treatment does not respond to
tocilizumab.33 117–120
Panel recommendations
For patients participating in clinical trials using CAR
T cells, toxicity should be assessed and managed as
per study protocols.
►► Patients treated with CAR T cells or blinatumomab
should be monitored vigilantly for signs of CRS and
neurotoxicity including (but not limited to) fever,
hypotension, and altered mental state.
►► The management of CRS or neurotoxicity secondary
to approved CAR T cell therapy or blinatumomab
should follow established guidelines.
►►

PATIENT SUPPORT AND QUALITY OF LIFE (QOL)
CONSIDERATIONS
While immunotherapy may provide a significant and
durable antitumor response for many patients, the appropriateness of any treatment option ultimately depends on
patient-specific considerations. Although the likelihood
for deep and durable response is the utmost priority in
treatment selection, it is important to consider the potential effects on patient satisfaction and QoL for a planned
intervention. Several analyses of QoL during chemotherapy in patients with acute leukemia have found that
intensive induction regimens are linked to detrimental
physical and psychological effects, such as fatigue, loss of
physical function, and depression.121 122 However, several
studies have also found that, in general, QoL improves
significantly when patients are in remission.121 122

Immunotherapies offer the potential for prolonged
remissions in some subsets of patients. Yet, although
the side effects of immunotherapy might be more tolerable for patients than those that accompany cytotoxic
drugs, the toxicities associated with immunotherapeutic
approaches may be life-threatening in some cases; for
example, CRS due to CAR T cell and BiTE therapies and
VOD/SOS after some ADCs. Thorough patient education, as well as ongoing dialog among all members of a
patient’s care team, is critical to ensure that the individualized and unique aspects of immunotherapy are understood, as well as the importance of promptly reporting
any toxicity.
Due to the rapidly evolving nature of the field, relatively few large-scale QoL assessments directly comparing
immunotherapeutic approaches with SOC treatment
for patients with acute leukemia have been completed.
From the available literature, however, recently approved
immunotherapies compare favorably with intensive
chemotherapy and allo-HCT in terms of patient-reported
outcomes and QoL.
An analysis of patient outcomes in the phase III TOWER
study of blinatumomab in adults with RR Ph− B-
cell
precursor ALL found patients who were treated with SOC
chemotherapy (n=95) reported significant deteriorations
in several functional measures (physical, role, and social)
and symptoms as measured by the 30-item European Organization for Research and Treatment of Cancer Quality of
Life Questionnaire (QLQ-C30) and markedly decreased
overall global health status/QoL scores relative to blinatumomab. Furthermore, the time to clinically meaningful
deterioration in HRQL or death was delayed for blinatumomab versus chemotherapy across all EORTC QLQ-C30
scales.123 n the phase III INO-VATE trial, patients with RR
B-ALL who received inotuzumab ozogamicin 124reported
better QOL, functioning, and symptom scores (except
for constipation and emotional functioning).124 Similarly,
an analysis of 58 patients with RR B-ALL aged 8–23 years
treated with tisagenlecleucel in the phase II ELIANA trial
demonstrated improvements in patient-
reported QoL
scores for all measures at month 3 after infusion with a
mean change from baseline of 13.3 (95% CI, 8.9 to 17.6)
for the pediatric quality of life inventory (PedsQL) total
score and 16.8 (95% CI, 9.4 to 24.3) for the EQ-5D Visual
Analogue Scale.20
Depending on the immunotherapeutic agent used,
hospitalization and monitoring during dosing and in
the subsequent weeks may be required, which can affect
a patient’s QoL and ability to work. For example, blinatumomab requires continuous intravenous infusion over
4 weeks and hospitalization is recommended for the first
9 days of the first cycle for RR disease and 3 days of hospitalization for cycle 1 in the MRD setting. Additionally,
patients are advised to refrain from driving and engaging
in hazardous occupations or operating heavy or potentially dangerous machinery while receiving blinatumomab.31 Tisagenlecleucel requires patients to stay within
proximity of their treatment center for the first month
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after infusion and, patients must be monitored two to
three times during the first 7 days after treatment.46
Financial distress related to cancer also takes a substantial toll on patient QoL.125 Immunotherapies for leukemia
are expensive. Importantly, patients may incur additional
expenses, such as transportation to and from the hospital
or accommodations nearby during treatment, further
highlighting that unequal access to these emerging
therapies.
Despite high prices, immunotherapeutic agents fare
favorably in cost-effectiveness analyses, offering significant
gains in life years and QoL years (quality-adjusted life years
(QALYs)) for patients. A recent cost-effectiveness study of
CAR T cell therapy versus SOC for pediatric patients with
B-ALL found that tisagenlecleucel had a total discounted
cost of US$667,000 (including hospital stays and other
expenses), with 10.34 discounted life years gained and
9.28 QALYs gained, which amounted to an incremental
cost-effectiveness ratio of approximately US$42,000 per
life year gained and approximatelyUS$46,000 per QALY
gained compared with clofarabine.126 In adults with RR
Ph− B-ALL, blinatumomab was found to yield 1.92 additional life years and 1.64 additional quality-adjusted life
years (QALYs) compared with SOC at an incremental cost
of US$180,642. The incremental cost-effectiveness ratio
for blinatumomab vs SOC was estimated to be $110,108/
QALY gained in the base case.127 In the UK, the National
Institute for Health and Care Excellence estimated
substantial improvement in survival with inotuzumab
ozogamicin compared with SOC, providing an additional
5.2 life years and 2.2 QALYs.128The deterministic incremental cost-effectiveness ratio was between £33,749 and
£37,497 per quality-adjusted life-year gained compared
with standard of care.
Panel recommendations
Prior to being treated with immunotherapy, patients
and caregivers should be educated about potential
AEs and given clear instructions for call parameters
for any toxicities.
►► Study protocols for new, investigational agents should
incorporate QoL assessment using validated tools.
►►

CONCLUSION
Once almost universally fatal, the 5-year survival rate for
acute leukemia has risen to 63% in the US.129 The advent
of immunotherapy has expanded the available options
in the treatment repertoire for acute leukemia, although
progress has been slower in the AML setting. Every year,
novel agents including BiTEs, CAR T cell therapies, and
ADCs continue to demonstrate impressive response rates
with favorable toxicity profiles across a variety of disease
states. Despite these advances, many patients remain ineligible for immunotherapeutic treatments, and relapses
after some of the newer modalities remain associated
with a very poor prognosis. In the future, the indications
for existing therapies are likely to continue to expand
and novel agents with potentially distinct mechanisms
14

of actions will be approved. Promising areas for future
research in leukemia include improvements in CAR
constructs and combining CAR T cell therapies with
other immunotherapy approaches as well as the development of additional bispecific monoclonal antibodies. In
AML specifically, there is great potential in efforts aimed
at targeting novel proteins that might be more effective
or more specific to early leukemia progenitors for novel
antibodies such as CLL1, WT1, and PR1 as well as the
development of CAR T cells for myeloid leukemias with
‘off switches’ to minimize long-term myelosuppression.
Therefore, as the field continues to develop, these recommendations will be updated.
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